Evidence map›Paper›PMID 42886421›Full record

ReviewMolecular biology reports2026

Modeling Moyamoya disease using patient-derived induced pluripotent stem cells and organoids.

Jong-Tae Kim, Dong Hyuk Youn, Harry Jung, Ji Hyeon Lee, Eun Pyo Hong, Youngmi Kim, Kyu-Won Cho, Jae Jun Lee, Jin Pyeong Jeon

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jong-Tae Kim *Institute of New Frontier Research Team, Hallym University College of Medicine, Chuncheon, 24252, Republic of Korea.
Dong Hyuk Youn *Institute of New Frontier Research Team, Hallym University College of Medicine, Chuncheon, 24252, Republic of Korea.
Harry JungInstitute of New Frontier Research Team, Hallym University College of Medicine, Chuncheon, 24252, Republic of Korea.
Ji Hyeon LeeInstitute of New Frontier Research Team, Hallym University College of Medicine, Chuncheon, 24252, Republic of Korea.
Eun Pyo HongInstitute of New Frontier Research Team, Hallym University College of Medicine, Chuncheon, 24252, Republic of Korea.
Youngmi KimInstitute of New Frontier Research Team, Hallym University College of Medicine, Chuncheon, 24252, Republic of Korea.
Kyu-Won ChoDepartment of Biomedical Informatics, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, 24253, Republic of Korea.
Jae Jun LeeInstitute of New Frontier Research Team, Hallym University College of Medicine, Chuncheon, 24252, Republic of Korea. iloveu59@hallym.or.kr.
Jin Pyeong JeonDepartment of Neurosurgery, Hallym University College of Medicine, Gyo-dong, Chuncheon-si, Gangwon-do, 24253, Republic of Korea. jjs6553@hanmail.net.

Funding

a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea HR21C0198Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education RS-2025-25397793the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) RS-2022-NR070859
6 · The paper itself

Abstract

The underlying mechanisms of Moyamoya disease (MMD), a rare, progressive cerebrovascular disorder marked by distal internal carotid artery stenosis or occlusion and the formation of fragile collaterals, remain poorly understood, in part because conventional models fail to capture the genetic, vascular, and neurovascular complexity of human MMD. Driven by recent advances in disease modeling, MMD research has moved beyond early endothelial progenitor cell studies toward patient-derived induced pluripotent stem cell (iPSC)-based platforms. Here, we summarize the generation and validation of MMD-specific iPSCs and their differentiation into endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and related vascular lineages, and we discuss how two-dimensional (2D) iPSC-based models have provided insights into impaired angiogenesis, endothelial dysfunction, abnormal VSMC behavior, and disrupted vascular cell interactions. We then highlight the emerging use of three-dimensional vascular and neurovascular organoids, which reproduce cellular heterogeneity, vessel-like organization, and neurovascular unit interactions more closely than conventional 2D cultures. These models may provide a more integrated platform for investigating the complex vascular pathophysiology of MMD. Finally, we discuss future directions for MMD modeling, including the integration of multi-omics profiling and CRISPR-mediated genome editing with patient-derived iPSC and organoid platforms. These approaches may help clarify genotype-phenotype relationships, RNF213-dependent and RNF213-independent mechanisms, and disease-relevant molecular pathways. With further standardization and validation, iPSC- and organoid-based models could support mechanistic studies, therapeutic screening, and personalized disease modeling. Our review underscores the emerging role of patient-derived stem cell and organoid technologies in advancing MMD research and in informing future translational efforts.

Indexed as

Induced Pluripotent Stem CellsMoyamoya DiseaseOrganoidsAnimalsCell DifferentiationEndothelial CellsHumansModels, BiologicalMyocytes, Smooth MuscleBrain organoidsDisease modelingInduced pluripotent stem cellsMoyamoya diseaseVascular organoids

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.